Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers
- PMID: 1401909
Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers
Abstract
The fine specificities of antibodies to the circumsporozoite (CS) protein of Plasmodium falciparum, present in the sera of volunteers immunized with irradiated P. falciparum sporozoites, were defined and compared to those of sera from persons living in a malaria-endemic area in West Africa. The specificity of these anti-CS antibodies was determined by ELISA, using recombinant proteins and synthetic peptides containing repeat and nonrepeat sequences of this CS protein. All 10 serum samples of the five sporozoite-immunized volunteers displayed very high antibody titers to the immunodominant repeat (NANP)n of the CS protein. However, only three of the serum samples of these vaccinees reacted with a single nonrepeat region and only at low titers. In contrast, a high percentage of sera from adults living in the malaria-endemic area who had been exposed to sporozoites, as well as liver and blood stages of P. falciparum, had high antibody levels, not only to the repeats but also to several nonrepeat regions of the CS protein. Furthermore, a number of sera from children living in this endemic area displayed appreciable levels of antibodies to the nonrepeat regions, in the absence of any antirepeat reactivity. Sera of Saimiri monkeys, which had undergone multiple blood-induced P. falciparum infections, consistently contained high titers of antibodies to several nonrepeat sequences of the CS protein, whereas only a few of these sera had low titers of antirepeat antibodies. Antibody binding sites, in nonrepeat regions, were mapped using synthetic polymers containing multiple copies of selected C-terminal sequences of the P. falciparum CS protein. The binding to sporozoites of antibodies to nonrepeat regions of the CS protein was determined. The basis for the differences in antibody binding sites of sera from persons immunized with irradiated sporozoites, compared to those from an endemic area, is discussed.
Similar articles
-
Quantitative Plasmodium sporozoite neutralization assay (TSNA).J Immunol Methods. 2004 Sep;292(1-2):157-64. doi: 10.1016/j.jim.2004.06.017. J Immunol Methods. 2004. PMID: 15350520
-
Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors.Am J Trop Med Hyg. 1996 Oct;55(4):424-9. doi: 10.4269/ajtmh.1996.55.424. Am J Trop Med Hyg. 1996. PMID: 8916800
-
Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum.J Immunol. 1993 Feb 15;150(4):1403-12. J Immunol. 1993. PMID: 7679427
-
T cell responses to repeat and non-repeat regions of the circumsporozoite protein detected in volunteers immunized with Plasmodium falciparum sporozoites.Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:223-7. doi: 10.1590/s0074-02761992000700037. Mem Inst Oswaldo Cruz. 1992. PMID: 1364202 Review.
-
Experimental basis for the development of a synthetic vaccine against Plasmodium falciparum malaria sporozoites.Ciba Found Symp. 1986;119:150-63. doi: 10.1002/9780470513286.ch9. Ciba Found Symp. 1986. PMID: 2426050 Review.
Cited by
-
Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.Infect Immun. 2004 Nov;72(11):6519-27. doi: 10.1128/IAI.72.11.6519-6527.2004. Infect Immun. 2004. PMID: 15501783 Free PMC article. Clinical Trial.
-
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.N Engl J Med. 2015 Nov 19;373(21):2025-2037. doi: 10.1056/NEJMoa1505819. Epub 2015 Oct 21. N Engl J Med. 2015. PMID: 26488565 Free PMC article. Clinical Trial.
-
Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites.PLoS One. 2012;7(12):e51692. doi: 10.1371/journal.pone.0051692. Epub 2012 Dec 26. PLoS One. 2012. PMID: 23300556 Free PMC article.
-
Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure.BMC Med. 2019 Feb 25;17(1):45. doi: 10.1186/s12916-019-1277-x. BMC Med. 2019. PMID: 30798787 Free PMC article.
-
Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection.J Exp Med. 2018 Jan 2;215(1):63-75. doi: 10.1084/jem.20170869. Epub 2017 Nov 22. J Exp Med. 2018. PMID: 29167197 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources